BOŠKOVIĆ L[au] - Search Results

Year	Number of Results
1970	1
1977	1
2010	1
2011	1
2013	1
2015	1
2016	2
2017	2
2019	1
2020	2
2021	3
2022	0

1

Nanoparticle Generation in Glowing Wire Generator: Insight into Nucleation Peculiarities.

Fomenko E, Altman I, Boskovic L, Agranovski IE. Fomenko E, et al. Among authors: boskovic l. Materials (Basel). 2021 Dec 16;14(24):7775. doi: 10.3390/ma14247775. Materials (Basel). 2021. PMID: 34947368 Free PMC article.

2

Trends in molecular characteristics and antimicrobial resistance of group B streptococci: a multicenter study in Serbia, 2015-2020.

Kekic D, Gajic I, Opavski N, Kojic M, Vukotic G, Smitran A, Boskovic L, Stojkovic M, Ranin L. Kekic D, et al. Among authors: boskovic l. Sci Rep. 2021 Jan 12;11(1):540. doi: 10.1038/s41598-020-79354-3. Sci Rep. 2021. PMID: 33436658 Free PMC article.

3

Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta.

Vrdoljak E, Magri C, Gamulin M, Bošković L, Omrčen T, Bajić Ž, Dienes T, Geczi L. Vrdoljak E, et al. Among authors: boskovic l. Neoplasma. 2021 Jan;68(1):208-215. doi: 10.4149/neo_2020_200512N519. Epub 2020 Sep 16. Neoplasma. 2021. PMID: 32940046

4

Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta.

Vrdoljak E, Jakopović M, Geczi L, Bogos K, Bošković L, Magri C, Bitar L, Bajić Ž, Samaržija M. Vrdoljak E, et al. Among authors: boskovic l. J Oncol. 2020 Nov 29;2020:9246758. doi: 10.1155/2020/9246758. eCollection 2020. J Oncol. 2020. PMID: 33376489 Free PMC article.

5

Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.

Ušjak D, Ivković B, Božić DD, Bošković L, Milenković M. Ušjak D, et al. Among authors: boskovic l. Microb Pathog. 2019 Jun;131:186-196. doi: 10.1016/j.micpath.2019.04.015. Epub 2019 Apr 10. Microb Pathog. 2019. PMID: 30980878

6

Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries.

Bošković L, Gašparić M, Petrić Miše B, Petković M, Gugić D, Ban M, Jazvić M, Dabelić N, Belac Lovasić I, Vrdoljak E. Bošković L, et al. Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12514. Epub 2016 May 5. Eur J Cancer Care (Engl). 2017. PMID: 27145728

7

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.

Vrdoljak E, Boban M, Omrcen T, Hrepic D, Fridl-Vidas V, Boskovic L. Vrdoljak E, et al. Among authors: boskovic l. Neoplasma. 2011;58(2):172-8. doi: 10.4149/neo_2011_02_172. Neoplasma. 2011. PMID: 21275468 Clinical Trial.

8

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors.

Bošković L, Gašparić M, Petković M, Gugić D, Lovasić IB, Soldić Ž, Miše BP, Dabelić N, Vazdar L, Vrdoljak E. Bošković L, et al. Breast. 2017 Feb;31:16-19. doi: 10.1016/j.breast.2016.10.018. Epub 2016 Oct 27. Breast. 2017. PMID: 27810693

9

Persistence of primary MALT lymphoma of the urinary bladder after rituximab with CHOP chemotherapy and radiotherapy.

Bacalja J, Ulamec M, Rako D, Bošković L, Trnski D, Vrdoljak E, Krušlin B. Bacalja J, et al. Among authors: boskovic l. In Vivo. 2013 Jul-Aug;27(4):545-9. In Vivo. 2013. PMID: 23812229

10

Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.

Vrdoljak E, Mise BP, Lukić B, Curić Z, Bosković L, Tica I. Vrdoljak E, et al. Among authors: boskovic l. Onkologie. 2010;33(1-2):53-6. doi: 10.1159/000264615. Epub 2010 Jan 5. Onkologie. 2010. PMID: 20164663

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results